← Human Trials & Peer-Reviewed Studies

Electronic Cigarette Vaping with Nicotine Causes Increased Thrombogenicity and Impaired Microvascular Function in Healthy Volunteers: A Randomised Clinical Trial.

Plain-language guide to PMID 37548804 (2023): double-blind randomized controlled trial of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID
37548804
Journal
Cardiovascular toxicology
Year
2023
Study type
Randomized Controlled Trial
Authors
Lyytinen G et al. (11 authors)
DOI
10.1007/s12012-023-09802-9
Registered trial
NCT04175457

What This Study Did, in Plain Language

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

Microvascular function was assessed at baseline and 30 min after exposure by laser speckle contrast imaging and iontophoresis of acetylcholine and sodium nitroprusside (SNP) to evaluate the endothelium-dependent and independent pathways of vasodilation.

Why It Was Studied

To further evaluate the impact of EC use on vascular health, the researchers investigated the effects of brief EC inhalation on flow-dependent thrombus formation and microcirculation in healthy volunteers.

The study was performed with a randomised double-blind crossover design.

Who Took Part

The age groups tagged for this paper are teenagers, young adults, adults and middle-aged adults.

Twenty-two healthy subjects aged between 18 and 45 years with occasional tobacco use were recruited.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).

In the crossover set-up each of the participants took both Therapeutic nicotine (patch, non-peptide) and the comparison in turn, acting as their own control.

What Was Measured

To further evaluate the impact of EC use on vascular health, the researchers investigated the effects of brief EC inhalation on flow-dependent thrombus formation and microcirculation in healthy volunteers.

Blood samples were collected at baseline and at 15 and 60 min following exposure and analysed with the Total-Thrombus-formation analysis system evaluating fibrin-rich thrombus formation and platelet thrombus formation in whole blood under flow.

PubMed files the paper under topics including Nicotine, Vaping, Electronic Nicotine Delivery Systems, Aerosols and Fibrin.

The authors tagged it with the keywords Coagulation, E-cigarette, Electronic cigarette, Microcirculation, Platelets and Thrombosis.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Therapeutic nicotine (patch, non-peptide).

The publication is from 2023 (Cardiovascular toxicology), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.